QuickChek – May 21, 2021



Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300

Onconova announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel multi-kinase inhibitor

Research, News & Market Data on Onconova

Watch recent presentation from NobleCon17



Aurania Reports Elevated Silver-Zinc Has Been Discovered In Outcrop Over 2.7 Kilometres At Tiria-Shimpia

Aurania Resources announced that follow-up of a high-grade boulder found in a stream has led to the discovery of silver-zinc mineralization

Research, News & Market Data on Aurania Resources

Watch recent presentation from NobleCon17



ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development

ProMIS Neurosciences announced PMN310 potential best in class antibody candidate for treatment of Alzheimer’s disease

Research, News & Market Data on ProMIS Neurosciences

Stay up to date. Follow us:

Release – ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development


ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development

 

PMN310 potential best in class antibody candidate for treatment of Alzheimer’s disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 21, 2021– ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310. This key first step in the manufacturing of antibody therapeutics will be carried out by Selexis, SA, using Selexis’ proprietary SUREtechnology Platform™. 

“ProMIS’ lead antibody program PMN310 offers potential “best in class” antibody therapy for Alzheimer’s disease”, stated ProMIS Executive Chairman Eugene Williams. “With initiation of producer cell line development, we are re-focusing our efforts on advancing PMN310 into clinical development with the support of a distinguished Boston-based group of investors.” 

After two years of setbacks in the Alzheimer’s disease (AD) field, 2021 has seen tremendous progress and reason for optimism.  Positive data from Lilly and Cassava, in addition to Biogen’s  June 7 PDUFA date for aducanumab, portend potential positive momentum for AD patients.  

ProMIS is poised to contribute to the field.  As stated by Gene Williams, “Using our proprietary discovery platform we were able to create the PMN310 antibody so that it selectively targets only the toxic oligomers of amyloid-beta (A?) and avoids undesirable binding to non-toxic forms of amyloid. We believe this high degree of selectivity of PMN310 may offer significant differentiation in terms of efficacy and safety compared to less selective antibody products from Biogen, Eisai, and Lilly.” 

PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A?, a recognized root cause of AD. Importantly, PMN310 does not appreciably bind to A? plaque or vascular deposits of A? thereby reducing the likelihood of brain swelling (edema), a dose-limiting side effect observed with non-selective therapeutic antibodies that interact with A? plaque. The current cell line development is based on an IgG1 isotype format (rather than the originally envisaged IgG4 format) as data from the scientific literature indicate that an IgG1 isotype may achieve greater efficacy via engagement of the immune system to clear damaging A? oligomers from the brain. 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information about ProMIS Neurosciences, please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

 

For Investor Relations please contact:

Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Release – Aurania Resources Reports Elevated Silver-Zinc Has Been Discovered In Outcrop Over 2.7 Kilometres At Tiria-Shimpia


Aurania Reports Elevated Silver-Zinc Has Been Discovered In Outcrop Over 2.7 Kilometres At Tiria-Shimpia

 

Toronto, Ontario, May 21, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports that follow-up of a high-grade boulder found in a stream has led to the discovery of silver-zinc mineralization in outcrop over 2.7 kilometres (“km”) in the Tiria-Shimpia target area in the Company’s Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.

Follow-up exploration, together with the on-going channel sampling of the mineralized layers where they are exposed at surface, is providing key information on the distribution of grade on surface within the 15km trend along which silver-zinc is located at Tiria-Shimpia. This trend was recently extended to a total of 22km after the discovery of a 7km long mineralized zone at Shimpia North (see press release dated April 30, 2021).  Within the 2.7km mineralized zone, there is a 500 metre (“m”) segment of high-grade material with silver up to 73 grams per tonne (“g/t”) and zinc up to 49% (Figure 1).  The high-grade mineralization is open to the north where there is a gap in outcrop of about 1km.

The mineralized sedimentary layer corresponds closely with silver enrichment in soil (Figure 1) and remains open to the south.  In fact, there is a second band of elevated silver in soil that suggests that there is a second mineralized layer in the sedimentary strata, but no outcrop has yet been found of the suspected second layer. A third level of mineralization has been found to the west with the discovery of low-grade outcrop that returned up to 2% zinc.  Zinc and silver enrichment continues to the southern limit of ridge and spur soil sampling, and there is therefore potential for the silver-zinc zone to extend further south.

Figure 1.  Plan view of the distribution of elevated silver in soil (orange shapes) and geological faults (black ticked lines) in the Tiria-Shimpia area showing the location of rock samples from outcrop over a 2.7km trend within the 15km-long Tiria-Shimpia target.

Geological Details of the Area Sampled

Silver-zinc mineralization is concentrated in the sedimentary layering in crackle-brecciated dolomitic limestone.  Sphalerite and barite occur in veinlets and as fill between rock fragments in the breccia.  The mineralization occurs in sedimentary layering that is folded across north-northwest – trending hinge lines.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 

Laboratories: The soil samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.

Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% zinc and lead, and 100g/t silver, 0.4g of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Dr. Richard Spencer

President

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

EuroDry Ltd. (EDRY) – Good News of Solid Results New Charter and Fleet Expansion Drives Price Target Higher

Friday, May 21, 2021

EuroDry Ltd. (EDRY)
Good News of Solid Results, New Charter and Fleet Expansion Drives Price Target Higher

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands and trades on the NASDAQ Capital Market under the ticker EDRY. EDRY is the product of a spin-off of the dry bulk fleet by Euroseas (ESEA) completed in May 2018. For every five ESEA shares, ESEA shareholders received one EDRY share. There are currently ~2.2 million EDRY shares outstanding. EuroDry operates in the dry bulk shipping markets. EuroDry’s operations are managed by Eurobulk Ltd., an affiliated ship management company, and Eurobulk FE (Far East) Ltd, which are responsible for the day-to-day commercial and technical management and operation of the fleet. EuroDry employs the fleet on spot and period charters and through pool arrangements.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adjusted 1Q2021 EBITDA stronger than expected due to higher TCE rates. 1Q2021 EBITDA of $4.0 million (adjusted for dry dock expenses) was slightly higher than expected due to higher-than-expected TCE rates of $14,924/day. TCE revenue of $9.4 million was above expectations due to the positive impact of TCE rates tied to indices. The fleet of 7.0 vessels did not change and ownership days were 630 with 0 idle days.

    Fleet expanding.  The Blessed Luck, a 2004-built Panamax, will be acquired shortly for $12.1 million. The acquisition will be financed with 8% debt, including a seller note of $5 million and a bridge loan of $6 million from a related party. Discussions on more permanent financing are under way and the new loan should financing about 65% of the acquisition, or ~$8 million. The Blessed Luck will be …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300


Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300

 

Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors

NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel multi-kinase inhibitor. The trial is expected to include three U.S. sites that will enroll patients with advanced cancer including, but not limited to, HR+ HER 2- metastatic breast cancer patients who are refractory to, or progressing on, currently approved CDK 4/6 inhibitors.

The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of ON 123300 administered orally as monotherapy at increasing doses starting at 40 mg daily for consecutive 28-day cycles. Following completion of the dose-escalation phase of the trial and once the recommended Phase 2 dose (RP2D) is established, additional patients with HR+ HER 2- metastatic breast cancer with at least one prior line of therapy, which are expected to include approved CDK 4/6 inhibitors, will be enrolled into the trial with the intent to identify signals of efficacy. Additional cancer indications are also under consideration for study, and will be chosen based on preclinical and developing data.

“We are excited to begin dosing patients in this Phase 1 study and are pleased to be advancing ON 123300’s clinical development in the United States,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova Therapeutics. “Our goal is to provide an innovative treatment option for patients with advanced breast cancer who have become resistant to the commercial CDK 4/6 inhibitors, and other refractory solid tumors driven by the overexpression of tyrosine kinases targeted by ON 123300. Notably, ON 123300’s ability to target multiple kinase pathways that are overexpressed in cancer may allow for single-agent efficacy and better tolerability compared to existing treatment regimens.”

Dr. Fruchtman added, “We are also pleased by the progress our partner HanX Biopharmaceuticals is making with their ongoing Phase 1 trial with ON 123300 in China. While the administration schedule differs between these two Phase 1 trials, the maximum tolerated dose has not yet been reached in the first two dose-escalation cohorts of this trial, which is a promising sign for ON 123300’s safety profile. Collectively, we expect these two complementary Phase 1 studies to provide important insights that will inform the design of subsequent trials.”

For more information on the U.S. Phase 1 clinical trial of ON 123300 see ClinicalTrials.gov identifier: NCT04739293.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ non-small cell lung cancer with oral rigosertib in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

The Sustainability of Growing Margin Debt


image credit: Mikhail Nilov (Pexels)


Margin Debt Increases are Eye-Popping

 

Stock market margin debt jumped by $25 billion in April and $48.5 billion since the beginning of the year based on FINRA statistics. The level reached a historic high of $847 billion from $552.5 billion a year ago. This 53% increase in a year is growth well above average. The unsustainability of this pace, and the idea that margin rates charged by brokers will rise as interest rates do, add an overlooked element of risk in today’s stock market.

The seeming precariousness of the level of leverage measures only two types of accounts, this includes brokerage accounts and advisory customers that are overseen by FINRA. It excludes unreported borrowing by professionals and others that have used debt for investments in the financial markets.

 

 

The below graph shows weekly data on the growth of margin debt reported by FINRA. The current pace is faster than at any point found on the FINRA website. The market, as measured by the S&P 500, is following the same path of growth (see second chart). Although correlation is not proof of cause; experience has shown that as the market rises, people will borrow to compound their returns. Further, as the value of the accounts that serve as collateral then rise, they are capable of leveraging up even more.

 

 

The snowball effect of the increases in both the S&P performance and the borrowing that is in part fueling the market increases could continue until something disrupts the chain reaction.

 

Possible Disruptors to Margin and Market Growth

This disruption could come in the form of an increase in interest rates. This would cause brokers to raise their broker’s call rate.  Investors would then have to weigh their expected return versus the cost of the borrowing. The cost of borrowed funds to the expected return equation would not be as favorable even if their market view has not changed. This could cause some investors to retreat from their aggressive position. It wouldn’t take much at these levels to create a chain reaction of selling to reduce borrowed capital.

Another potential disruptor could be a few bad days in a row for the market. Again this impacts expected return versus the cost of (borrowed) money. The chart above suggests just how large the profits are that many investors are sitting on. A few days of market decline can signal ti investors that it’s time to book some of those profits. This further weakness could trigger enough margin calls where investors either sell positions and pay off the interest, or cough up additional cash. The margin calls could create a march downward as the same forces that brought it up, act in reverse to tear it down.

 

 

Other Borrowing

In a previous article, Channelchek reported that 2.5 million homes or 4.9% of homeowners’ mortgages are in forbearance. The hurdle to pause payment on a federal agency-backed mortgage is quite low. It’s suspected that some of this money that will be owed later has been finding its way into the market. In reality, this is borrowed money, and the payments are (under current stipulations) required to resume by mid-year 2021. This could curtail the flow of these borrowed funds, not accounted for by FINRA, from entering the market. The reduced inflows and possible outflows would reduce investment growth and the upward pressure on prices.

In another Channelchek article, we described how family offices are not overseen by regulatory authorities like FINRA, any borrowing from money managers is not accounted for in much the same way hedge fund borrowing is not regulated or overseen. The leverage from these investment groups is not known. Earlier this year, there was an instance when the firm Archegos Capital Management suffered losses large enough to impact markets and earnings of some of their large banking relationships. The amount of risk and, therefore, the potential impact on the market to trade-off from this category is not known.

 

Take-Away

The strength of the market comes from many places. The amount of cash in the system undoubtedly has driven prices up. The low return on interest rate investment alternatives is another which pushed money into higher-risk investments, and then there is the availability of borrowed money. The use of borrowed money is at historic highs.

Borrowed money has a cost. That cost is measured against the expected return. If the expectations change or the cost of money increases, the market could sink to find a new balance from which to try to build again. Just as sure as markets go up and down, this will occur to some degree. Why a selloff may be triggered is debt-funded investing. When a larger selloff may be triggered, is unknown.

 

Suggested Reading:

Is Inflation Going to Hurt Stocks?

The Limits of Government Economic Tinkering (June 2020)



A Look at Real Estate Risks to the Stock Market

Understanding Family Offices

 

Sources:

https://www.finra.org/investors/learn-to-invest/advanced-investing/margin-statistics

https://www.federalreserve.gov/publications/files/financial-stability-report-20210506.pdf

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – EuroDry Ltd. Reports Results for the Quarter Ended March 31 2021


EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2021 and Announces Agreement to Acquire M/V Blessed Luck, a 2004-Japanese Built Panamax Bulker

 

ATHENS, Greece, May 20, 2021 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three-month period ended March 31, 2021 and an agreement to acquire M/V Blessed Luck, a 76,704 dwt drybulk vessel built in Japan.

First Quarter 2021 Highlights:

  • Total net revenues of $8.6 million; net income of $0.9 million; net income attributable to common shareholders (after a $0.3 million dividend on Series B Preferred Shares and a $0.1 million preferred deemed dividend arising out of the net redemption of approximately $3 million of Series B Preferred Shares in the first quarter of 2021) of $0.4 million or $0.19 earnings per share basic and diluted. Adjusted net income attributable to common shareholders1 for the period was $1.3 million or $0.55 earnings per share basic and diluted.
  • Adjusted EBITDA1 was $4.0 million.
  • An average of 7.0 vessels were owned and operated during the first quarter of 2021 earning an average time charter equivalent rate of $14,924 per day.
  • The Company declared a dividend of $0.3 million on its Series B Preferred Shares. The dividend will be paid in cash.

1Adjusted EBITDA, Adjusted net income/(loss) and Adjusted earnings/(loss) per share are not recognized measurements under US GAAP (GAAP) and should not be used in isolation or as a substitute for EuroDry’s financial results presented in accordance with GAAP. Refer to a subsequent section of the Press Release for the definitions and reconciliation of these measurements to the most directly comparable financial measures calculated and presented in accordance with GAAP.

M/V Blessed Luck Acquisition

The Company also announced that it has agreed to acquire M/V Blessed Luck, a 76,704 dwt drybulk vessel built in 2004 in Japan, for $12.12 million. The vessel is majority owned by a third party and has been managed by Eurobulk Ltd., also the manager of three of the Company’s vessels. The vessel is expected to be delivered to the Company within May 2021. The acquisition will be financed partly by a short term sellers’ credit of $5 million and an one year bridge loan of $6 million provided by an entity affiliated with the Company’s Chief Executive Officer with the remaining funds coming from the Company; both the sellers’ credit and short term loan carry an annual interest of 8%. In parallel, the Company is in the process of arranging a bank loan with the acquired vessel as collateral, expected to be finalized within approximately three months, which will provide sufficient funds to repay the sellers’ credit and, possibly, part of the bridge loan. At the same time, the Company entered into a charter agreement for the vessel for a period between a minimum of 11 months and a maximum of 13 months at a rate of $19,500/day which will commence upon delivery of the vessel and contribute about $4 million of EBITDA during the minimum period of the charter.

Aristides Pittas, Chairman and CEO of EuroDry commented:
“In stark contrast to a year ago, it has been a very positive 2021 so far with drybulk rates rebounding significantly as a result of solid trade growth and limited supply growth. The latter, especially, is constrained by short and medium term factors: in the short term, by inefficiencies in the vessel-port transportation system that resulted from COVID-19 effects and required protocols and, in the medium term, by the lowest orderbook in the last 20+ years. We believe that the market is likely to remain strong for the next couple of years provided that demand for transportation of drybulk cargoes – which is generally linked to economic activity – will maintain at least a historically average growth rate; it is noteworthy that the IMF, amongst others, predicts that economic activity will rebound above historical average levels as the world recovers from the COVID-19 pandemic.

In such a positive environment, our main strategy is to try to expand our fleet in a risk efficient way despite our limited funds available for investment. Thus, we acquired M/V Blessed Luck, a 2004-built vessel, with a combination of seller and affiliate bridge loans to complement our cluster of medium age Japanese-built Panamax-size vessels alongside our cluster of own-built newbuildings. The acquisition of M/V Blessed Luck will increase our fleet to eight units and is expected to contribute to a proportional increase in our EBITDA. At the present market rate levels, we are to accumulate funds that will provide us with several investment or expansion options or shareholder reward models. We, further, believe that the strong drybulk markets enhance the value of our public listing as a consolidation platform and we continuously investigate opportunities to take advantage of it.”

Tasos Aslidis, Chief Financial Officer of EuroDry commented:
“Our net revenues for the first quarter of 2021 were higher by 69.3% as compared to the first quarter of 2020. This was the result of higher average charter rates by 89.3% earned during the quarter as compared to the first quarter of 2020 and 38.7% higher when compared to the fourth quarter of 2020.

Total daily vessel operating expenses, including management fees, general and administrative expenses, but excluding drydocking costs, increased by approximately 8.5% during the first quarter of 2021 compared to the same quarter of last year. This increase is mainly due to increased crewing costs in 2021 compared to 2020, resulting from difficulties in crew rotation due to COVID-19 related restrictions.

Adjusted EBITDA during the first quarter of 2021 was $4.0 million compared to $0.6 million achieved for the first quarter of last year. As of March 31, 2021, our outstanding debt (excluding the unamortized loan fees) was $56.0 million versus restricted and unrestricted cash of approximately $6.2 million.”

First Quarter 2021 Results:
For the first quarter of 2021, the Company reported total net revenues of $8.6 million representing a 69.3% increase over total net revenues of $5.1 million during the first quarter of 2020, which was the result of the higher time charter rates our vessels earned during the first quarter of 2021. The Company reported net income for the period of $0.9 million and net income attributable to common shareholders of $0.4 million, as compared to a net loss and a net loss attributable to common shareholders of $2.3 million and $2.6 million, respectively, for the same period of 2020. For the first quarter of 2021, a gain on bunkers resulted in positive voyage expenses of $0.3 million for the period as compared to voyage expenses of $0.4 million in the same period of 2020. Depreciation expenses for the first quarter of 2021 were $1.7 million compared to $1.6 million for the same period of 2020. Vessel operating expenses were $3.1 million for the first quarter of 2021 compared to $2.8 million in the same period of 2020, mainly due to increased crewing costs in the first quarter of 2021 compared to the corresponding period in 2020, resulting from difficulties in crew rotation due to COVID-19 related restrictions. Management fees and general and administrative expenses remained unchanged at $0.5 million and $0.6 million, respectively, for the first quarter of 2021 as compared to the same period of last year.

Interest and other financing costs for the first quarter of 2021 amounted to $0.6 million, slightly decreased as compared to $0.7 million for the same period of 2020. Interest during the first quarter of 2021 was lower due to lower average debt during the period and the decreased Libor rates of our loans during the period as compared to the same period of last year. For the three months ended March 31, 2021, the Company recognized a $1.6 million loss on derivatives, comprised of $0.7 million realized loss and $1.1 million unrealized loss of forward freight agreements and $0.2 million gain on three interest rate swaps as compared to a loss on interest rate swaps of $0.3 million for the same period of 2020.

On average, 7.0 vessels were owned and operated during the first quarter of 2021 earning an average time charter equivalent rate of $14,924 per day compared to 7.0 vessels in the same period of 2020 earning on average $7,885 per day.

Adjusted EBITDA for the first quarter of 2021 was $4.0 million compared to $0.6 million achieved during the first quarter of 2020.

Basic and diluted earnings per share attributable to common shareholders for the first quarter of 2021 was $0.19 calculated on 2,291,471 basic and 2,320,577 diluted weighted average number of shares outstanding, compared to basic and diluted loss per share of $1.17 for the first quarter of 2020, calculated on 2,267,375 basic and diluted weighted average number of shares outstanding.

Excluding the effect on the earnings attributable to common shareholders for the quarter of the unrealized loss on derivatives, the adjusted earnings attributable to common shareholders for the quarter ended March 31, 2021 would have been $0.55 per share basic and diluted, compared to an adjusted loss of $0.91 per share basic and diluted for the quarter ended March 31, 2020, after excluding the effect of the unrealized loss on derivatives and the loss on write-down of inventory. Usually, security analysts do not include the above items in their published estimates of earnings per share.

Fleet Profile:

The EuroDry Ltd. fleet profile is as follows:

Name Type Dwt Year
Built
Employment(*) TCE Rate ($/day)
Dry Bulk Vessels          
EKATERINI Kamsarmax 82,000 2018 TC until Mar-22 Hire 106% of the
Average Baltic
Kamsarmax P5TC(***)
index
XENIA Kamsarmax 82,000 2016 TC until Aug-22 Hire 105% of the
Average Baltic
P5TC(***) index
ALEXANDROS P. Ultramax 63,500 2017 Guardian
Navigation GMax
LLC Pool
Pool revenue from
August 2018
EIRINI P Panamax 76,466 2004 TC until Jun-21 Hire 99%
of Average
BPI(**) 4TC
STARLIGHT Panamax 75,845 2004 TC until Aug-21 Hire 98.5%
of Average
BPI(**) 4TC
TASOS Panamax 75,100 2000 TC until Jun-21 $19,750
PANTELIS Panamax 74,020 2000 TC until May-21 $10,450
Total Dry Bulk Vessels 7
528,931      
Vessel agreed to be acquired          
BLESSED LUCK
Panamax 76,704 2004 TC until April-22 $19,500
Total on a fully delivered basis 8 605,635      

Note:
(*)        Represents the earliest redelivery date.
(**)      BPI stands for the Baltic Panamax Index; the average BPI 4TC is an index based on four time charter routes.
(***)    The average Kamsarmax Baltic P5TC Index is an index based on five Panamax time charter routes.



Summary Fleet Data:

  Three months,
ended

March 31, 2020
Three months,
ended

March 31, 2021
FLEET DATA    
Average number of vessels (1) 7.0   7.0  
Calendar days for fleet (2) 637.0   630.0  
Scheduled off-hire days incl. laid-up (3) 9.9   0.0  
Available days for fleet (4) = (2) – (3) 627.1   630.0  
Commercial off-hire days (5) 0.0   0.0  
Operational off-hire days (6) 0.0   0.0  
Voyage days for fleet (7) = (4) – (5) – (6) 627.1   630.0  
Fleet utilization (8) = (7) / (4) 100.0 % 100.0 %
Fleet utilization, commercial (9) = ((4) – (5)) / (4) 100.0 % 100.0 %
Fleet utilization, operational (10) = ((4) – (6)) / (4) 100.0 % 100.0 %
     
AVERAGE DAILY RESULTS    
Time charter equivalent rate (11) 7,885   14,924  
Vessel operating expenses excl. drydocking expenses (12) 5,130   5,694  
General and administrative expenses (13) 925   877  
Total vessel operating expenses (14) 6,055   6,571  
Drydocking expenses (15) 342   13  

(1) Average number of vessels is the number of vessels that constituted the Company’s fleet for the relevant period, as measured by the sum of the number of calendar days each vessel was a part of the Company’s fleet during the period divided by the number of calendar days in that period.

(2) Calendar days. We define calendar days as the total number of days in a period during which each vessel in our fleet was owned by us including off-hire days associated with major repairs, drydockings or special or intermediate surveys or days of vessels in lay-up. Calendar days are an indicator of the size of our fleet over a period and affect both the amount of revenues and the amount of expenses that we record during that period.

(3) The scheduled off-hire days including vessels laid-up are days associated with scheduled repairs, drydockings or special or intermediate surveys or days of vessels in lay-up.

(4) Available days. We define available days as the total number of Calendar days in a period net of scheduled off-hire days incl. laid up. We use available days to measure the number of days in a period during which vessels were available to generate revenues.

(5) Commercial off-hire days. We define commercial off-hire days as days a vessel is idle without employment.

(6) Operational off-hire days. We define operational off-hire days as days associated with unscheduled repairs or other off-hire time related to the operation of the vessels.

(7) Voyage days. We define voyage days as the total number of days in a period during which each vessel in our fleet was in our possession net of commercial and operational off-hire days. We use voyage days to measure the number of days in a period during which vessels actually generate revenues or are sailing for repositioning purposes.

(8) Fleet utilization. We calculate fleet utilization by dividing the number of our voyage days during a period by the number of our available days during that period. We use fleet utilization to measure a company’s efficiency in finding suitable employment for its vessels and minimizing the amount of days that its vessels are off-hire for reasons such as unscheduled repairs or days waiting to find employment.

(9) Fleet utilization, commercial. We calculate commercial fleet utilization by dividing our available days net of commercial off-hire days during a period by our available days during that period.

(10) Fleet utilization, operational. We calculate operational fleet utilization by dividing our available days net of operational off-hire days during a period by our available days during that period.

(11) Time charter equivalent rate, or TCE, is a measure of the average daily net revenue performance of our vessels. Our method of calculating TCE is determined by dividing time charter revenue and voyage charter revenue net of voyage expenses by voyage days for the relevant time period. Voyage expenses primarily consist of port, canal and fuel costs that are unique to a particular voyage, which would otherwise be paid by the charterer under a time charter contract or are related to repositioning the vessel for the next charter. TCE is a standard shipping industry performance measure used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., spot voyage charters, time charters, pool agreements and bareboat charters) under which the vessels may be employed between the periods. Our definition of TCE may not be comparable to that used by other companies in the shipping industry.

(12) Daily vessel operating expenses, which include crew costs, provisions, deck and engine stores, lubricating oil, insurance, maintenance and repairs and management fees are calculated by dividing vessel operating expenses and management fees by fleet calendar days for the relevant time period. Drydocking expenses are reported separately.

(13) Daily general and administrative expense is calculated by dividing general and administrative expenses by fleet calendar days for the relevant time period.

(14) Total vessel operating expenses, or TVOE, is a measure of our total expenses associated with operating our vessels. TVOE is the sum of vessel operating expenses, management fees and general and administrative expenses; drydocking expenses are not included. Daily TVOE is calculated by dividing TVOE by fleet calendar days for the relevant time period.

(15) Drydocking expenses include expenses during drydockings that would have been capitalized and amortized under the deferral method divided by the fleet calendar days for the relevant period. Drydocking expenses could vary substantially from period to period depending on how many vessels underwent drydocking during the period. The Company expenses drydocking expenses as incurred.

Conference Call and Webcast:
Today, May 20, 2021 at 09:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results. 

Conference Call details:
Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553-9962 (US Toll Free Dial In), 0(808) 238- 0669 (UK Toll Free Dial In) or +44 (0) 2071 928592 (Standard International Dial In). Please quote “EuroDry” to the operator. 

A replay of the conference call will be available until Thursday, May 27, 2021. The United States replay number is 1(866) 331-1332; from the UK 0(808) 238-0667; the standard international replay number is (+44) (0) 3333 00 9785 and the access code required for the replay is: 2489743#.  

Audio webcast – Slides Presentation:
There will be a live and then archived audio webcast of the conference call, via the internet through the EuroDry website (www.eurodry.gr). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. A slide presentation on the First Quarter 2021 results in PDF format will also be available 10 minutes prior to the conference call and webcast accessible on the company’s website (www.eurodry.gr) on the webcast page. Participants to the webcast can download the PDF presentation. 


EuroDry Ltd.
Unaudited Consolidated Condensed Statements of Operations
(All amounts expressed in U.S. Dollars – except number of shares)

  Three Months
Ended

March 31,
Three Months
Ended

March 31,
  2020
2021
   
Revenues    
Time charter revenue 5,345,554   9,096,187  
Commissions (280,046 ) (522,486 )


Net revenues
5,065,508   8,573,701  
     
Operating expenses    
Voyage expenses, net 400,637   (305,902 )
Vessel operating expenses 2,778,543   3,061,055  
Drydocking expenses 217,675   7,921  
Vessel depreciation 1,626,258   1,651,870  
Related party management fees 489,566   526,400  
General and administrative expenses 589,534   552,523  
Loss on write-down of inventory 255,200    
Total Operating expenses (6,357,413 ) (5,493,867 )
     
Operating (loss) / income (1,291,905 ) 3,079,834  
     
Other income / (expenses)    
Interest and other financing costs (664,427 ) (595,817 )
Loss on derivatives, net (340,976 ) (1,620,344 )
Foreign exchange gain / (loss) 669   (2,472 )
Interest income 3,544   3,325  
Other expenses, net (1,001,190 ) (2,215,308 )
Net (loss) / income (2,293,095 ) 864,526  
Dividend Series B Preferred shares (354,826 ) (299,570 )
Preferred deemed dividend   (120,000 )
Net (loss) / income attributable to common shareholders (2,647,921 ) 444,956  
(Loss) / earnings per share, basic & diluted (1.17 ) 0.19  
Weighted average number of shares, basic 2,267,375   2,291,471  
Weighted average number of shares, diluted 2,267,375   2,320,577  


EuroDry Ltd.
Unaudited Consolidated Condensed Balance Sheets
(All amounts expressed in U.S. Dollars – except number of shares)

  December 31,
2020
March 31,
2021
     
ASSETS  
Current Assets:    
Cash and cash equivalents 938,282   2,085,456  
Trade accounts receivable, net 1,528,055   2,663,752  
Other receivables 460,209   537,313  
Inventories 1,385,280   487,280  
Restricted cash 1,518,036   2,198,274  
Prepaid expenses 226,033   173,037  
Due from related companies   387,393  
Total current assets 6,055,895   8,532,505  
     
Fixed assets:    
Vessels, net 99,305,990   97,678,758  
Long-term assets:    
Restricted cash 2,150,000   1,900,000  
Total assets 107,511,885   108,111,263  
     
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY    
Current liabilities:    
Long term bank loans, current portion 13,793,754   14,100,581  
Trade accounts payable 1,074,518   907,155  
Accrued expenses 704,508   719,363  
Accrued preferred dividends   299,570  
Derivatives 456,133   1,543,641  
Deferred revenue 246,125   665,504  
Due to related companies 2,984,759    
Total current liabilities 19,259,797   18,235,814  
     
Long-term liabilities:    
Long term bank loans, net of current portion 37,318,084   41,588,509  
Derivatives 393,899   128,191  
Total long-term liabilities 37,711,983   41,716,700  
Total liabilities 56,971,780   59,952,514  
     
Mezzanine equity:        
Series B Preferred shares (par value $0.01, 20,000,000 preferred shares authorized, 16,606 and 13,606 shares issued and outstanding, respectively) 15,940,713   13,060,713  
     
Shareholders’ equity:    
Common stock (par value $0.01, 200,000,000 shares authorized, 2,348,216 issued and outstanding, respectively) 23,482   23,482  
Additional paid-in capital 53,048,060   53,101,748  
Accumulated deficit (18,472,150 ) (18,027,194 )
Total shareholders’ equity 34,599,392   35,098,036  
Total liabilities, mezzanine equity and shareholders’ equity 107,511,885   108,111,263  
     


EuroDry Ltd.
Unaudited Consolidated Condensed Statements of Cash Flows
(All amounts expressed in U.S. Dollars)

  Three Months
Ended March
31,
  Three Months
Ended March
31,
 
2020   2021  
     
Cash flows from operating activities:  
Net (loss) / income (2,293,095 ) 864,526  
Adjustments to reconcile net (loss) / income to net cash provided by / (used in) operating activities:    
Vessel depreciation 1,626,258   1,651,870  
Amortization and write off of deferred charges 35,176   169,251  
Share-based compensation 62,106   53,688  
Loss on write-down of inventory 255,200    
Unrealized loss on derivatives 329,047   821,801  
Changes in operating assets and liabilities (206,623 ) (3,360,484 )
Net cash (used in) / provided by operating activities (191,931 ) 200,562  
     
Cash flows from investing activities:    
Cash paid for vessels capitalized expenses (189,950 ) (31,240 )
Net cash used in investing activities (189,950 ) (31,240 )
     
Cash flows from financing activities:    
Redemption of preferred shares   (3,000,000 )
Preferred dividends paid (358,726 )  
Loan arrangement fees paid   (250,000 )
Proceeds from long-term debt   31,700,000  
Repayment of long-term debt (2,002,000 ) (27,042,000 )
Net cash (used in) / provided by financing activities (2,360,726 ) 1,408,000  
     
Net increase / (decrease) in cash, cash equivalents and restricted cash (2,742,607 ) 1,577,412  
Cash, cash equivalents and restricted cash at beginning of period
9,129,442   4,606,318  
Cash, cash equivalents and restricted cash at end of period 6,386,835   6,183,730  
     

Cash breakdown

Cash and cash equivalents 3,284,024   2,085,456  
Restricted cash, current 402,811   2,198,274  
Restricted cash, long term 2,700,000   1,900,000  
Total cash, cash equivalents and restricted cash shown in the statement of cash flows 6,386,835   6,183,730  


EuroDry Ltd.
Reconciliation of Adjusted EBITDA to Net (loss) / income
(All amounts expressed in U.S. Dollars)

  Three Months
Ended

March 31, 2020
Three Months
Ended

March 31, 2021
Net (loss) / income (2,293,095 ) 864,526  
Interest and other financing costs, net (incl. interest income) 660,883   592,492  
Vessel depreciation 1,626,258   1,651,870  
Unrealized loss on Forward Freight Agreement derivatives   1,069,980  
Loss / (gain) on interest rate swap derivatives 340,976   (174,513 )
Loss on write-down of inventory 255,200    

Adjusted EBITDA
590,222   4,004,354  

Adjusted EBITDA Reconciliation:
EuroDry Ltd. considers Adjusted EBITDA to represent net income / (loss) before interest, income taxes, depreciation, unrealized (gain) / loss on Forward Freight Agreements (FFAs), (gain) / loss on interest rate swaps and loss on write-down of inventory. Adjusted EBITDA does not represent and should not be considered as an alternative to net income / (loss), as determined by United States generally accepted accounting principles, or GAAP. Adjusted EBITDA is included herein because it is a basis upon which the Company assesses its financial performance because the Company believes that this non-GAAP financial measure assists our management and investors by increasing the comparability of our performance from period to period by excluding the potentially disparate effects between periods of, financial costs, unrealized (gain) / loss on FFAs, (gain) / loss on interest rate swaps, loss on write-down of inventory, and depreciation. The Company’s definition of Adjusted EBITDA may not be the same as that used by other companies in the shipping or other industries. 

EuroDry Ltd.
Reconciliation of Net (loss) / income to Adjusted net (loss) / income
(All amounts expressed in U.S. Dollars – except share data and number of shares)

  Three Months
Ended
March 31, 2020
Three Months
Ended
March 31, 2021
 
Net (loss) / income (2,293,095 ) 864,526  
Unrealized loss on derivatives 329,047   821,801  
Loss on write-down of inventory 255,200    
Adjusted net (loss) / income (1,708,848 ) 1,686,327  
Preferred dividends (354,826 ) (299,570 )
Preferred deemed dividend   (120,000)  

Adjusted net (loss) / income attributable to common shareholders
(2,063,674 ) 1,266,757  
Adjusted (loss) / earnings per share, basic & diluted (0.91 ) 0.55  
Weighted average number of shares, basic 2,267,375   2,291,471  
Weighted average number of shares, diluted 2,267,375   2,320,577  

Adjusted net income / (loss) and Adjusted income / (loss) per share Reconciliation:

EuroDry Ltd. considers Adjusted net income / (loss) to represent net income / (loss) before unrealized (gain) / loss on derivatives and loss on write-down of inventory. Adjusted net income / (loss) and Adjusted earnings / (loss) per share is included herein because we believe it assists our management and investors by increasing the comparability of the Company’s fundamental performance from period to period by excluding the potentially disparate effects between periods of unrealized (gain) / loss on derivatives and loss on write-down of inventory, which may significantly affect results of operations between periods. Adjusted net income / (loss) and Adjusted earnings / (loss) per share do not represent and should not be considered as an alternative to net income / (loss) or earnings / (loss) per share, as determined by GAAP. The Company’s definition of Adjusted net income / (loss) and Adjusted earnings / (loss) per share may not be the same as that used by other companies in the shipping or other industries.

About EuroDry Ltd.
EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd into a separate listed public company. EuroDry was spun-off from Euroseas Ltd on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. 

EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day-to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

After the delivery of M/V Blessed Luck, the Company will have a fleet of 8 vessels, including 5 Panamax drybulk carriers, 1 Ultramax drybulk carrier and 2 Kamsarmax drybulk carriers. EuroDry’s 8 drybulk carriers have a total cargo capacity of 605,635 dwt.

Forward Looking Statement
This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for dry bulk vessels, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

Visit our website www.eurodry.gr

Company Contact Investor Relations / Financial Media
Tasos Aslidis
Chief Financial Officer
EuroDry Ltd.
11 Canterbury Lane,
Watchung, NJ07069
Tel. (908) 301-9091
E-mail: [email protected]
Nicolas Bornozis
President
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, NY10169
Tel. (212) 661-7566
E-mail: [email protected]

QuickChek – May 20, 2021



EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2021 and Announces Agreement to Acquire M/V Blessed Luck, a 2004-Japanese Built Panamax Bulker

EuroDry Ltd announced its results for the three-month period ended March 31, 2021

Research, News & Market Data on EuroDry

Watch recent presentation from NobleCon17



PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

PDS Biotechnology announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO)

Research, News & Market Data on PDS Biotech

Watch recent presentation from PDS Biotech



Esports Entertainment Group, Inc. Reports Fiscal 2021 Third Quarter Financial Results

Esports Entertainment Group announced financial results for its fiscal 2021 third quarter ended March 31, 2021

Olympic Esports Involvement Can Serve Investors Well

Research, News & Market Data on Esports Entertainment Group

Watch recent presentation from EEG



Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares

Onconova Therapeutics announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021

Onconova reports Q1 2021 Financial Results

Research, News & Market Data on Onconova

Watch recent presentation from NobleCon17



Orion Group Holdings, Inc. Announces Contract Awards of Approximately $17 Million

Orion Group Holdings announced three contract awards for its Concrete segment in each of its key markets, totaling approximately $17 million

See today’s research report on Orion Group Holdings from Poe Fratt, Senior Research Analyst at Noble Capital Markets

Research, News & Market Data on Orion Group Holdings

Watch recent presentation from NobleCon17



Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights

Ceapro Inc. announced financial results and operational highlights for the first quarter ended March 31, 2021

Research, News & Market Data on Ceapro

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

 


PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

 

Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy

FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8. The presentation, scheduled for June 7, is expected to include results from a larger sample than the 14 patients included in the abstract.

Additional data highlights from abstract #2501 include:

  • An overall objective response rate of 71% (10/14) in patients with refractory HPV16-associated cancers
    • 1 complete response (anal cancer)
    • 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer)
  • 90% of these of these responses are ongoing after a median 5 months of follow up (9/10)

The NCI Center for Cancer Research’s Laboratory of Tumor Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading this Phase 2 trial (NCT04287868), which studies PDS0101 in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824), a bifunctional “trap” fusion protein targeting TGF-? and PD-L1, and NHS-IL12 (M9241), a tumor-targeting immunocytokine. Bintrafusp alfa is being jointly developed by Merck KGaA, Darmstadt, Germany, and GlaxoSmithKline; NHS-IL12 is being developed by Merck KGaA, Darmstadt, Germany.

The trial is evaluating the treatment combination in both checkpoint inhibitor naïve and refractory patients with advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment. Objective response is measured by radiographic tumor responses according to RECIST 1.1. These reported data validate the preclinical studies published by the NCI demonstrating that the complementary mechanisms of action of the three immunotherapies which involve potent in-vivo HPV16-specific killer and helper T-cell induction with effective T-cell tumor infiltration, blocking of immune checkpoints as well as targeting of TGF-? resulted in superior tumor regression.

“The achievement of a 71% objective response rate in a difficult to treat patient population continues to strengthen the evidence of our novel Versamune® platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer resulting in strong synergy with Bintrafusp alfa and NHS-IL12, thus leading to effective tumor regression,” commented Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. “The initial data solidifies our belief that PDS0101’s published preclinical efficacy, when combined with these two immune-modulating agents, demonstrates the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV-associated cancers who have limited treatment options.”

There are more than 630,000 cases of HPV-associated malignancies including cervical, oropharyngeal and anal cancer worldwide annually. HPV 16 is responsible for most of these cases. About 15-20% of HPV-associated malignancies respond to PD-(L)1 inhibitors. However, for the overwhelming majority of patients who progress on these immunotherapies there is no effective standard of care therapy.

The abstract is now available online on the ASCO conference website: https://am.asco.org/.

Abstract Number: 2501
Abstract Title: Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.

Presenting Author: Julius Strauss, MD, National Cancer Institute
Session: Developmental Therapeutics—Immunotherapy
Date: June 7, 2021
Time: 3:00 PM-6:00 PM EDT

Dr. Julius Strauss, Staff Clinician, LTIB, is serving as the Principal Investigator of this phase 2 clinical trial in advanced HPV-associated cancers. For patients interested in enrolling in this clinical study, please call NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email [email protected], and/or visit the website: https://trials.cancer.gov.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products may overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple investigational therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: [email protected]

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: [email protected]

*Updated data and results to be presented in June at the ASCO meeting
1C.S. Rumfield et al., J. Journal for ImmunoTherapy of Cancer 2020;8:e000612. doi:10.1136/jitc-2020-000612)
2S. Gandhapudi et al, J. Immunology, 2019 (202), 1215

The Technological Invasion in Cannabis Cultivation


image credit: Oregon Dept. of Agr. (Flikr)


Robotics and AI Are Being Tapped by Cannabis Growers

 

Increasing market demand and challenges in farming cannabis crops have prompted farms to seek technological upgrades to improve cultivation. Introducing robotics and artificial intelligence (AI) in Cannabis cultivation is having a massive impact on its production processes.

Related to cultivation, the use of tech has improved output and quality in a number of ways. Firstly, the crops are healthier. It has also made planting, monitoring, and harvesting more efficient. Companies are also integrating high tech into other stages of the production processes, from seed to delivery and right through to methods of consumption.

 

Why AI is a Game-Changer

Despite the upfront costs, high-tech saves growers money and increases output. With more states legalizing the use of cannabis, farmers benefit from a consistent product and improved yield. According to the Grand View Research Report, the “growing legalization and the adoption of marijuana for the treatment of chronic diseases are the key factors driving the growth of the market”. Dependability is critical for growers. Farmers are reinvesting profits to introduce technology that will improve the production process and resultant crops in order to satisfy market demand.

One advantage of the technological invasion of cannabis farming is it provides solutions to the planting environment issues. One solution is well-monitored indoor farming; this avoids many of the challenges of outdoor farming. From environmental challenges to the risk of cross-pollination, choosing indoor farming controls many key factors in producing cannabis.

Getting the THC concentration, temperature, and other figures right are key parts of farming cannabis in a monitored, legal setting. While indoor farming addresses these issues, it is expensive to maintain. With artificial intelligence, the management system is simpler and less expensive using automated systems and monitoring. It also can also aid the detection of pests and other threats.

The stakes are high for growers. The current global market for cannabis is $20.5 billion. Grand View Research has predicted that the global market for cannabis will be worth $73.6 Billion by 2027. With healthier, more consistent crops produced in larger quantities, some of this demand can be met without equal land expansion.

 

Cannabis Companies Benefitting from AI

High tech has found its way into the marijuana industry from seed through distribution. Below are three interesting publicly traded companies and information on how they’re benefiting from technology.

Medicine Man Technologies, Inc., d/b/a Schwazze (OTCQX: SHWZ), is a growing vertically integrated cannabis company located in Colorado but planning to spread its wings into other states. They operate seed to sale with work ethics that integrates customer-centric thinking and data science to test, measure, and drive decisions and outcomes in every stage of the production chain. Their implementation of technology in improving their operations is driven by their belief in the full potential of cannabis.

Sugarmade, Inc. (OTCMKTS: SGMD) is a company that improves customer satisfaction by integrating technology in service delivery. The delivery of cannabis is made easier and faster for customers with their technological approaches. Sugarmade has a portfolio of brands, within the recreational cannabis industry and outside, these include SugarRush, Budcars, NUG Avenue, and CarryOutsupplies.com.

Stem Holdings, Inc., d/b/a Driven by Stem (OTCQX: STMH), is a farm-to-home cannabis company providing solutions through high-tech innovation. Their business model is customer-driven as they have their own AI-based app delivery businesses throughout California that are expanding into the mature Oregon market.

 

 

Take-Away

Corporate farming of any kind relies on high tech, and cannabis is having its own set of demands and challenges, whether it is indoor or outdoor. Cannabis companies are increasing their reliance on data science and high-tech solutions like artificial intelligence to survive and improve success. With automated processes and machine-controlled methods, cannabis production is keeping up with the exponential growth that is set to reach new heights.

 

Suggested Content:

Will Federal Law Regarding Cannabis be Changed?

Cannabis Customers Served by “Ice Cream Truck” Delivery Model



Schwazze CEO, Justin Dye, and CFO, Nancy Huber Roadshow Replay (Video)

Stem Holdings C-Suite Interview with Adam Berk

 

Source:

https://www.grandviewresearch.com/press-release/global-legal-marijuana-market

https://www.globenewswire.com/news-release/2021/02/18/2177949/0/en/The-Worldwide-Cannabis-Industry-is-Projected-to-Reach-90-4-Billion-by-2026.html.

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Esports Entertainment Group Inc. Reports Fiscal 2021 Third Quarter Financial Results

 


Esports Entertainment Group, Inc. Reports Fiscal 2021 Third Quarter Financial Results

 

  • Third quarter Revenues of $5.4 Million, up 129% from previous quarter
  • Driven by completion of Lucky Dino asset purchase on 1st March
  • Performance bolstered by launch of SportNation.com and Vie.bet on Maltese Gaming Authority license during the quarter
  • Investment continued in building out Technology team and platform development as well as to achieve scale in back-office functions
  • Cash Jumps $11.3Million in 3Q21, Ending the Quarter at $16.9 Million with No Debt

Newark, New Jersey–(Newsfile Corp. – May 17, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (the “Company” or “EEG”), a diversified operator of esports, igaming and traditional sports betting businesses with a global footprint, today announced financial results for its fiscal 2021 third quarter ended March 31, 2021.

Fiscal 2021 Third Quarter Financial Results Highlights

  • Net revenue for 3Q21 of $5.4 million, up $5.4 million on 3Q20, (and up 129% as compared with 2Q21 net revenue of $2.4 million)
  • Gross profit (Net revenue less Cost of revenue) for 3Q21 of $3.1 million, up $3.1 million on 3Q20, (and up 199% as compared with $1.0 million in 2Q21)
  • Gross margin as a percentage of net sales in 3Q21 was 57.0%, (compared to 43.5% in 2Q21)
  • Sales and Marketing expenses of $2.4 million in 3Q21, up from $0.1m in 3Q20 (and compared to $1.9 million in 2Q21)
  • General and administrative expenses of $6.3 million in 3Q21, up from $0.5m in 3Q20 (and compared to $4.9 million in 2Q21)
  • Operating loss of $5.6 million in 3Q21, up from a loss of $0.6m in 3Q20 (and improved by 3% from a loss of $5.8 million in 2Q21)
  • Net loss of $12.4 million or $0.73 per basic common share in 4Q21, up from a net loss of $6.3m in 3Q20 or $1.02 per basic common share (and compared to a net loss of $7.3 million or $0.57 per basic common share in 2Q21)
  • Adjusted EBITDA* of -$2.1 million in 3Q21, compared to adjusted EBITDA of -$0.5m in 3Q20, and 44% improved from -$3.8 million adjusted EBITDA in 2Q21
  • Capital expenditures for 3Q21 of $0.7 million, up from $0.0m million in 3Q20 (and compared to $0.4m in 2Q21), as investment in Platform development continues
  • Stockholders’ equity at the end of 3Q21 increased by $50.0 million or 438% to $61.4 million from $11.4 million at the end of Fiscal 2020.

Operational Highlights

  • Completed asset purchase of Online Casino Operator Lucky Dino
  • Completed acquisition of Esports Gaming League (EGL), a provider of live and online events and tournaments
  • Closed $30 million registered direct offering priced at $15 per share
  • Vie.bet and SportNation.com brands launched on Malta Gaming Authority license, enabling operations in 150 jurisdictions globally
  • Filed New Jersey Gaming License Application
  • Signed exclusive Esports Tournament Partnerships with several pro-Sports teams, including the Baltimore Ravens, New England Patriots and Denver Broncos

*Adjusted EBITDA is a non-GAAP financial measure. Reconciliation is provided in the tables of this press release.

Management’s Comments

Our first quarter results were mainly driven by our acquisition of Lucky Dino combined with organic growth coming from our existing brands of Sportnation , EGL and Vie.gg.

We continue to execute on our organic growth strategy as well as acquire additional strategic esports and igaming assets.

Our recently announced partnerships with blue-chip professional sports organizations, are strong endorsements of this strategy. The imminent close of the previously announced GG circuit/Helix acquisition, combined with the recently announced intention to acquire Holodeck Media, will enable us to exponentially expand our technology-driven esports wagering, tournament play and igaming focused entertainment company.

We remain committed to the previously communicated full year fiscal 2021 revenue guidance, of $18m, and the Fiscal 2022 revenue guidance of $70m.

Our future is bright and we are very excited to continue our rapid expansion and growth driven by our unique assets and market position.

Fiscal 2021 Third Quarter Financial Results

Net revenues were $5.4 million for the three months ended March 31, 2021, as compared to $0.0million for the three months ended March 31, 2020, and were up by 129% (+$3.0m) when compared net revenues of $2.4m during the three-month period ended December 31, 2020. 9 months year-to-date revenues through 31st March, 2021 were $8.0m.

The quarter-on-quarter increase is primarily driven by the completion of the Lucky Dino Gaming Limited asset purchase on 1st March 2021, aided by the launch of both SportNation.com and Vie.bet into new jurisdictions under its Malta Gaming Authority (MGA) license

With the acquisition of Lucky Dino Gaming, Unique Active Players (“UAPs”) in the month of March across iGaming brands, rose to above 40,000, with Average Revenue per Player surpassing $80.

Total operating expenses for the three months ended March 31, 2021 totaled $11.0 million, an increase from the $0.6 million recorded for the three months ended March 31, 2020, and up from $8.1 million in the three-month period ending December 31, 2020. The increase was primarily attributable to the increased payroll, stock compensation, marketing, legal and professional services fees related to increased business activity.

Total net loss for the three months ended March 31, 2021 was $12.4 million, up from a loss of $6.3m in the three-month period ended March 31, 2020. This was principally driven by increased Equity Based Compensation, Transaction related costs, Depreciation and Change in the Fair value of Warrant liabilities, totaling $7.4 million between them.

*Adjusted EBITDA for the three months ended March 31, 2021 was -$2.1 million, up from -$0.6m in the three-month period ended March 31, 2020, but improved on the -$3.8m adjusted EBITDA in the three-month period ended December 31, 2020.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with Generally Accepted Accounting Principles (GAAP), the Company uses adjusted EBITDA, a non-GAAP financial measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses this non-GAAP financial measure for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that it provides useful information about operating results, enhances the overall understanding of past financial performance and future prospects, and allows for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP financial measure used by the Company in this press release may be different from the methods used by other companies.

We define and calculate Adjusted EBITDA as net loss before the impact of interest income or expense, income tax expense or benefit, depreciation and amortization, and further adjusted for the following items: stock-based compensation, transaction-related costs, non-core litigation, settlement and related costs, remeasurement of warrant liabilities, and certain other non-recurring, non-cash or non-core items, as described in the reconciliation below.

Adjusted EBITDA excludes certain expenses that are required in accordance with U.S. GAAP because they are non-recurring items (for example, in the case of transaction-related costs), non-cash expenditures (for example, in the case of depreciation, amortization, and stock-based compensation), or are not related to our underlying business performance (for example, in the case of interest income and expense and litigation settlement and related costs).

Esports Entertainment Group, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

March 31, June 30,
2021 2020
ASSETS
Current assets
Cash $ 16,880,683 $ 12,353,307
Restricted cash 3,428,366
Accounts receivable, net 153,011
Receivables reserved for users 1,486,024
Loans receivable 2,000,000
Other receivables 920,115
Deposit on business acquisition 500,000
Prepaid expenses and other current assets 1,423,581 263,345
Total current assets 26,291,780 13,116,652
Equipment, net 80,904 8,041
Operating lease right-of-use asset 546,012
Intangible assets, net 27,810,029 2,000
Goodwill 16,992,199
Other non-current assets 1,290,353 6,833
TOTAL ASSETS $ 73,011,277 $ 13,133,526
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses $ 5,305,176 $ 811,549
Liabilities to customers 3,218,798
Deferred revenue 145,091
Liabilities to be settled in stock 927,855
Notes payable – current 158,141
Operating lease liability – current 240,725
Contingent consideration 300,000
Total current liabilities 9,367,931 1,739,404
Notes payable 186,898
Deferred income taxes 1,729,138
Operating lease liability 322,205
TOTAL LIABILITIES 11,606,172 1,739,404
Commitments and contingencies (Note 13)
Stockholders’ equity
Preferred stock $0.001 par value; 10,000,000 shares authorized, none issued and
outstanding
Common stock $0.001 par value; 500,000,000 shares authorized, 20,166,740 and
11,233,223 shares issued and outstanding as of March 31, 2021 and June 30, 2020,
respectively 20,167 11,233
Additional paid-in capital 104,417,852 31,918,491
Accumulated deficit (42,077,212 ) (20,535,602 )
Accumulated other comprehensive loss (955,702 )
Total stockholders’ equity 61,405,105 11,394,122
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 73,011,277 $ 13,133,526

 

Esports Entertainment Group, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended March 31, Nine Months Ended March 31,
2021 2020 2021 2020
Net revenue $ 5,398,708 $ $ 7,983,293 $
Operating costs and expenses:
Cost of revenue 2,321,620 4,249,889
Sales and marketing 2,399,200 84,249 4,891,688 184,175
General and administrative 6,291,388 466,809 14,082,111 1,728,695
Total operating expenses 11,012,208 551,058 23,223,688 1,912,870
Operating loss (5,613,500 ) (551,058 ) (15,240,395 ) (1,912,870 )
Other income (expense):
Interest expense (23,479 ) (2,285,792 )
Net amortization of debt discount and premium on convertible debt (674,946 ) (1,225,205 )
Change in fair value of derivative liabilities (6,952,798 ) (5,865,451 )
Change in fair value of warrant liability (5,358,313 ) (4,729,924 )
Change in fair value of contingent consideration (1,305,804 ) (1,305,804 )
Loss on extinguishment of debt (2,795,582 )
Gain on warrant exchange 1,894,418 1,894,418
Other non-operating income (loss) (165,464 ) 32 (265,486 ) (25,779 )
Loss before income taxes (12,443,080 ) (6,307,831 ) (21,541,610 ) (12,216,261 )
Income tax
Net loss $ (12,443,080 ) $ (6,307,831 ) $ (21,541,610 ) $ (12,216,261 )
Basic and diluted loss per common share $ (0.73 ) $ (1.02 ) $ (1.54 ) $ (2.04 )
Weighted average number of common shares outstanding, basic and diluted 16,950,275 6,183,944 13,974,197 5,989,619

 

Adjusted EBITDA

The table below presents our Adjusted EBITDA reconciled to our net loss, the closest U.S. GAAP measure, for the periods indicated:

Esports Entertainment Group, Inc.

Adjusted EBITDA

Reconciliation to GAAP Results

Three months ended March 31, Nine months ended March 31,
2021 2020 2021 2020
Net loss $ (12,443,080 ) $ (6,307,830 ) $ (21,541,610 ) $ (12,216,261 )
Adjusted for:
Depreciation and amortization 882,951 2,486 1,687,161 18,013
Interest (income) expense, net 23,479 2,285,792
Stock-based compensation (1) 743,527 3,055,118 448,434
Transaction-related costs (2) 1,340,245 1,435,788
Litigation, settlement, and related costs (3) 508,689 508,689
Change in fair value of warrant liability 5,358,313 4,729,924
Change in fair value of contingent consideration 1,305,804 1,305,804
Loss on extinguishment of debt 2,795,582
Gain on warrant exchange (1,894,418 ) (1,894,418 )
Net amortization of debt discount and premium on convertible debt 674,946 1,225,205
Change in fair value of derivative liabilities 6,952,798 5,865,451
Other non-operating costs 165,464 33 265,486 25,779
Adjusted EBITDA $ (2,138,087 ) $ (548,506 ) $ (8,553,640 ) $ (1,446,423 )

 

(1) The amounts for the three months ended March 31, 2021 includes stock-based compensation expenses resulting from the issuance of equity awards to employees, non-employee directors and non-employee consultants for services.

(2) Includes transaction advisory, consulting, accounting and legal expenses for acquisition related activities

(3) Includes primarily external legal costs related to litigation and litigation settlement costs deemed unrelated to our core business operations.

Release – Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares


Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares

 

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis.

At Onconova’s 2021 reconvened annual meeting of stockholders on April 30, 2021, Onconova stockholders authorized the Company’s Board of Directors to amend the Tenth Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split at a ratio in the range of one-for-five to one-for-fifteen. Onconova’s Board of Directors subsequently approved a reverse stock split ratio of one-for-fifteen, and the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation to effect the reverse stock split, which became effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware on May 20, 2021.

  • Upon effectiveness of the reverse stock split, each fifteen shares of Onconova’s common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share.
  • In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, warrants, and convertible preferred stock entitling the holders to purchase shares of our common stock. In particular, at the effective time of the reverse stock split, the Company adjusted its outstanding tradable warrants currently trading on the Nasdaq Capital Market under the symbol “ONTXW” in accordance with the terms of such tradable warrants to reflect the reverse stock split. As a result of these adjustments (and the adjustments effected on September 25, 2018 for a prior one-for-fifteen reverse stock split of the Company’s Common Stock), each tradable warrant now entitles its holder to purchase one- two hundred and twenty-fifth (1/225) of a share of Onconova’s common stock at an exercise price of $1,107.00 per share of common stock.
  • No fractional shares will be issued as a result of the reverse stock split. Instead, Onconova’s stockholders who otherwise would have been entitled to a fraction of a share, will receive a full share of common stock. If a holder of the tradable warrant would be entitled to receive a fraction of a share upon the exercise of the warrant, such fractional share will be rounded down to the nearest whole share. Fractional shares resulting from exercise of other common stock warrants and conversion of outstanding convertible preferred stock (if any) will be rounded in accordance with the terms of such securities.
  • The reverse stock split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares.

Onconova’s transfer agent, EQ Shareowner Services, will provide instructions to stockholders of record regarding the process for exchanging share certificates and all book-entry or other electronic positions representing issued and outstanding shares of Onconova common stock will be automatically adjusted.

Onconova’s common stock will continue to trade on the Nasdaq Capital Market under the trading symbol “ONTX.” The new CUSIP number for the common stock following the reverse stock split is 68232V 801.

In addition, at the Company’s reconvened 2021 Special Meeting of Stockholders on April 30, 2021, the Company’s stockholders also approved a proposal to amend the Certificate of Incorporation to decrease, upon the effectiveness of the Reverse Stock Split, the number of authorized shares of capital stock of the Company from 255,000,000 to 130,000,000 shares in order to decrease the number of authorized shares of common stock from 250,000,000 to 125,000,000 shares (the “Authorized Shares Decrease”). On May 20, 2021, the Company filed the Certificate of Amendment for Authorized Shares Decrease (the “Authorized Shares Decrease Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Authorized Shares Decrease Certificate of Amendment became effective on May 20, 2021 upon the effectiveness of the Reverse Stock Split.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

Release – Orion Group Holdings Inc. Announces Contract Awards of Approximately $17 Million

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $17 Million

 

HOUSTON–(BUSINESS WIRE)–May 20, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced three contract awards for its Concrete segment in each of its key markets, totaling approximately 
$17 million.

The Company was awarded a contract from  Hensel Phelps to provide concrete services for the new 
Royal Caribbean Cruise Terminal in the 
Port of Galveston, Texas. The 
$5.5 million project calls for paving and tilt-wall construction for the facility with work expected to start during the second quarter with completion expected later this year.

The Company was also awarded a 
$6.5 million project in 
San Antonio, Texas, that requires the construction of four tilt-wall buildings and associated paving. This work will begin in the third quarter and be completed by the fourth quarter of this year.

In addition, the Company was awarded a 
$5.1 million contract to construct multiple tilt-wall buildings and perform site paving for a new business park northwest of the 
Dallas-Fort Worth area. The work under this contract will begin in the third quarter and be completed by the second quarter of 2022.

“These project awards are a direct result of the quality and professionalism our team provides our customers,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “We are also extremely excited for  Hensel Phelps providing our team the opportunity to be involved in the new 
Royal Caribbean Cruise Terminal, as this work represents a great example of cross-selling opportunities between segments for our services.”

About Orion Group Holdings 

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States
Alaska
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
[email protected]
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.